Rather than defining an AML subtype in itself, the B7 phenotype more likely offers a momentary perspective of the versatile interaction between leukemia and immune cells that could predict resistance to standard chemotherapy and could guide personalized immunotherapy. This evidence concerns the gene CD80 and leukemia.